Dexmetomidine With Erector Spinae Plane Block in Cholecystectomy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

November 10, 2022

Study Completion Date

November 10, 2022

Conditions
Dexmedtomidine in Erector Spinae Block for Laparscopic Cholecystectomy
Interventions
DRUG

dexmedetomidine as adjuvant with bupivacaine

to assess efficacy of adding dexmedetomidine as adjuvant with bupivacaine in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.

DRUG

Bupivacain only

to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.

Trial Locations (1)

31511

Tanta University Hospitals, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT05369468 - Dexmetomidine With Erector Spinae Plane Block in Cholecystectomy | Biotech Hunter | Biotech Hunter